ResApp share price rockets 28% on Pfizer takeover news

ResApp has received a takeover offer from an industry giant…

| More on:
Rocket powering up and symbolising a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ResApp shares are rocketing higher on Monday after the digital health company received a takeover approach
  • Healthcare giant Pfizer has tabled an 11.5 cents per share cash offer, which values the company at $100 million
  • The ResApp board unanimously recommends the offer subject to certain customary conditions

The ResApp Health Ltd (ASX: RAP) share price has exploded higher on Monday morning.

At the time of writing, the digital health company's shares are up a whopping 28% to 11.5 cents.

Why is the ResApp share price rocketing higher?

The ResApp share price is rocketing higher this morning after the company revealed that it has received a takeover offer from healthcare giant Pfizer.

According to the release, ResApp has entered into a binding scheme implementation deed with Pfizer, under which it will be acquired by way of a scheme of arrangement for 11.5 cents per share in cash. This represents a total equity value of approximately $100 million.

Subject to the independent expert determining that the scheme is in the best interests of ResApp shareholders, and in the absence of a superior proposal, the company's directors unanimously recommend that ResApp shareholders vote in favour of the scheme. They intend to vote shares under their control in favour of the proposed scheme.

This takeover approach comes less than three weeks after ResApp announced positive results for a new novel smartphone-based COVID-19 screening test. These results appear to have caught the eye of Pfizer, which has moved quickly to acquire the company.

ResApp's CEO and Managing Director, Tony Keating, commented: "We are excited by the prospect of this acquisition by Pfizer, a leading biopharmaceutical company that shares our vision and belief that technology can help transform healthcare and improve patients' lives."

"The proposed acquisition recognises the years of dedicated work by the ResApp team to build ResApp into a leader in audio-based analysis of respiratory health. We believe that the material premium and certainty of an all-cash consideration is an attractive outcome for our shareholders," Keating added.

ResApp has advised that shareholders needn't take any action at the present time. A scheme meeting is expected in mid June.

Today's gain means the ResApp share price is now up over 80% since this time last month.

Should you invest $1,000 in Resapp Health right now?

Before you buy Resapp Health shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Resapp Health wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 25% on big UK news

Investors are sending this ASX healthcare stock rocketing on Friday. But why?

Read more »

two men shake hands on a deal.
Healthcare Shares

Can you guess which ASX 300 healthcare stock is rocketing 34% on takeover news

This share is rocketing on Friday after accepting a takeover offer.

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Earnings Results

Telix share price jumps 13% on FY24 profit surge

This pharma stock has delivered another stunning result. Here's what it reported.

Read more »

Health professional working on his laptop.
Earnings Results

2 ASX 300 healthcare shares making big moves on earnings updates

Let's see what these two shares reported on Thursday.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

2 ASX 200 pharmaceutical shares surging on big US news

Big news is getting investors excited on Wednesday. Let's find out what is happening.

Read more »

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »